Predictive Test for Type 2 Diabetes Developed by GATC Health Could Be Industry First

New diabetes lateral flow test has potential to predict the onset of Type 2 diabetes years in advance and measure disease progression

IRVINE, Calif., Feb. 10, 2022 — GATC Health Corp, a biotech company revolutionizing drug discovery and disease prediction using artificial intelligence and advanced multiomics, today announced it has filed a provisional patent for a lateral flow assay that identifies individual risk of diabetes and predicts the likely rate of progression for those at risk. The company believes this is the first predictive tool for Type 2 diabetes risk. The 15-minute test is designed to help doctors and patients improve early prediction and treatment of diabetes, including the potential to delay the onset of the disease for higher risk individuals.

According to the Centers for Disease Control and Prevention (CDC) the total annual cost of diabetes in the U.S. alone is $327 billion with $1 out of every $4 in US health care costs spent on caring for people with diabetes.

Unlike current diabetes tests that only detect whether an individual already has the disease, GATC Health’s test has the potential to predict the individual’s future risk of developing diabetes. In addition, the test can be used as a tool to delay or prevent the onset of the disease with additional lifestyle or medical interventions.

Currently, there are no clinically validated tests which identify people predisposed with contracting diabetes. Diabetes tests today—including A1C, Fasting Blood Sugar, Glucose Tolerance and Random Blood Sugar—only determine if the patient is already diabetic or prediabetic.  Unfortunately, individuals testing positive for the disease by these tests are beyond the point of prevention and must focus on treatment. Diabetes is currently detected via blood tests or continuous glucose monitors which measure current levels of HbA1C, or glucose in the bloodstream. GATC Health is directly addressing this gap in the market with this predictive test for Type 2 diabetes.

The company developed this test using its proprietary artificial intelligence platform, Multiomics Advanced Technology™ (MAT). MAT can analyze all biological data sets (multiomics), including genomic data, allowing the GATC scientific team to a create a holistic multiomics system specific to diabetes. The system identified and extrapolated the key markers in the progression of the disease, which are then quantified in this test. GATC Health expects that once available, it will provide potentially life-changing information to physicians and their patients, as well as providing significant benefits to risk-bearing parties, like insurance companies.

“Over my history of diabetes research, we have been searching for key predictive factors that help identify those who are at higher risk of developing diabetes in the future. This significant discovery will dramatically improve diabetes diagnostic predictive testing which can be used to initiate protocols to delay or prevent the development of the disease entirely,” said Dr. Jonathan Lakey, Chair of GATC Health’s Scientific Advisory Board and Professor Emeritus Departments of Surgery and Biomedical Engineering, University of California Irvine. “I believe we have identified a new, highly effective tool that could substantially reduce the incidence and impact of diabetes worldwide.”

In development for over a year, the diabetes lateral flow test is built upon Dr. Lakey’s many years of research in diabetes at University of California Irvine and his interest in the effect of diabetes on a growing segment of the world’s population. GATC Health has leveraged research, case studies and numerous data sets in conjunction with its MAT platform to develop early models that identify a longer term of pathology and predictive pathways. This groundbreaking test further illustrates GATC Health’s commitment to advancing predictive medicine and accelerating drug discovery.

“This unique use of biomarker quantification in a lateral flow test for type 2 diabetes is further evidence that GATC Health’s advanced AI platform has the capability to improve patient care in powerful, non-obvious ways,” said Ian Jenkins, GATC Health’s Chief Scientific Officer. “We are also optimistic this discovery can be used as a companion diagnostic for potential drug candidates in our product pipeline.”

GATC Health’s diabetes lateral flow test will utilize a finger prick to extract a drop of blood that is processed using a cassette that is similar in appearance to a pregnancy test.  The test will then be processed at either a clinician’s office or mailed to a certified laboratory and read using a relatively inexpensive standard laser plate reader.

GATC Health is in the process of engaging partners to develop a prototype for pre-clinical testing, clinical trials, and necessary regulatory approvals.

# # #

About GATC HealthGATC Health Corp is a pioneering technology company using whole genome analysis and multiomics-based artificial intelligence to revolutionize disease detection and drug discovery. The company’s patented AI platform reduces risk, time and costs for life science companies by digitally reproducing the human body to find non-obvious answers to biology’s most complex questions. GATC Health is accelerating healthcare’s transition to predictive, individualized medicine.Disclaimer

The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities.  This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information.  The Company reserves the right to modify or amend the information contained herein.